Orofacial effects of antiretroviral therapies

Oral Diseases

Volumn 7, Issue 4, 2001, Pages 205-210

  Scully, C ^a,b   Dios, P Diz ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Antiretroviral; HIV; Oral

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; SULFONAMIDE; ZALCITABINE; ZIDOVUDINE;

BONE MARROW SUPPRESSION; CHEILITIS; ERYTHEMA MULTIFORME; FACE DISORDER; HUMAN; LICHENOID; MOUTH DISEASE; MOUTH ULCER; PARESTHESIA; PRIORITY JOURNAL; REVIEW; TASTE DISORDER; TOXIC EPIDERMAL NECROLYSIS; XEROSTOMIA;

EID: 0034901230     PISSN: 1354523X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1601-0825.2001.70401.x     Document Type: Review

References (72)

1. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection
2. Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine
3. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis
4. Positive effects of combined antiretroviral therapy on CD4+ T cells
5. Drug hypersensitivity reactions and human immunodeficiency virus disease
6. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects
7. HIV-1 viral load, phenotype and resistance in a subset of drug-naïve participants from the Delta trial
8. Cutaneous side effects induced by indinavir
9. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
10. Restoration of immunity to chronic hepatitis B infection in HIV-infection in HIV-infected patient on protease inhibitor
11. Adverse effects of antiretroviral therapy
12. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy
13. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: A prospective case control study
14. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonavir
15. Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program
16. A short-term study of the safety, pharmacokinetics and efficacy of ritonavir, an ihibitor of HIV-1 protease
17. Genotypic-resistance assays and anti-retroviral therapy
18. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
19. Regression of AIDS-related Kaposi's sarcoma following ritonavir therapy
20. Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitors therapy
21. Changing prevalence of human immunodeficiency virus-associated oral lesions
22. Xerostomia associated with didanosine
23. NNRTIs - A new class of drugs for HIV
24. Oral adverse effects of medical management in patients with HIV infection
25. Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200-500 CD4+ cells per cubic millimeter
26. Prevalence and incidence of oral lesions - The changing scene
27. White lichenoid lesions of the buccal mucosa in patients with HIV infection
28. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial
29. Cheilitis in association with indinavir
30. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults
31. Nail and mucocutaneous hyperpigmentation with azidothymidine therapy
32. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
33. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience
34. Cytomegalovirus after initiation of highly active antitretroviral therapy
35. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomised controlled comparison with zidovudine monotherapy
36. Combination therapies for HIV infection and genomic drug resistance
37. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
38. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treatment with an HIV-specific protease inhibitor, ritonavir
39. A controlled trial of zidovudine in primary human immunodeficiency virus infection
40. Active human immunodeficiency virus protease is required for viral infectivity
41. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxycytidine or AZT 2′3′-dideoxycytidine combination therapy
42. Effect of human immunodeficiency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeficiency virus-1-infected patients
43. HIV infection; oral lesions, CD4 cell count and viral load in an Italian study population
44. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
45. Dermatologic manifestations of AIDS
46. Dermatologic complications associated with administration of 2′,3′-dideoxycytidine in patients with human immunodeficiency virus infection
47. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomised, controlled trial
48. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-protease inhibitor
49. Patient-reported nonadherence to HAART is related to protease inhibitor levels
50. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS
51. Parotid lipomatosis in HIV positive patients: A new clinical disorder associated with protease inhibitors
52. Didanosine as probable cause of Stevens-Johnson syndrome
53. Changing prevalence of oral manifestations of human deficiency virus in the era of protease inhibitor therapy
54. Cutaneo-mucosal hyperpigmentation in AIDS. 4 Cases
55. HIV topic update: Protease inhibitor therapy and oral health care
56. Structure-assisted design of nonpeptide human immunodeficiency virus-1 protease inhibitors
57. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter
58. Effect of protease inhibitors on the sense of taste
59. Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy
60. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy
61. Tongue ulcer in azidothymidine-induced neutropenia. Rapid increase in neutrophils and healing of the ulcer by substitution of recombinant human granulocyte colony stimulating factor (rhG-CSF)
62. The HIV global pandemic; the development and emerging implications
63. Effects of HAART on natural history of AIDS-related opportunistic disorders
64. Line probe assay (LiPA) for rapid detection of drug-selected mutations in the HIV-1 reverse transcriptase gene
65. Antiretrovirals
66. Oral manifestations of HIV infection of predominantly ethnic Chinese
67. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient
68. Nevirapine-induced overlap Stevens-Johnson syndrome/toxic epidermal necrolysis
69. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis
70. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir